FGEN
Fibrogen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FGEN
Fibrogen, Inc.
A biopharmaceutical company that developing novel therapeutic agents to treat anemia, fibrotic disease, and cancer
350 Bay Street, Suite 100 #6009, San Francisco, CA 94133
--
Fibrogen, Inc., was incorporated in Delaware in 1993. The company is a biopharmaceutical company focused on the development of new therapies in the frontiers of cancer biology and anemia. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46 for the treatment of metastatic castration-resistant prostate cancer and potentially other cancers. The program also includes the development of FG-3180, a related CD46 targeted positron emission tomography biomarker and imaging agent.
Earnings Call
Q1/2025
Estimate EPS0.02
Actual EPS0.05
Estimate Revenue2.00M
Actual Revenue2.74M
FibroGen's Q1 2025 Earnings Call: Key Contradictions on Trial Eligibility, Commercial Opportunities, and Development Timelines
May 20,2025 07:26
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-2.25
Actual EPS-1.88
Estimate Revenue2.88M
Actual Revenue1.35M
FibroGen's 2025 Q2: Unraveling Key Contradictions in Roxadustat and FG-3246 Clinical Trial Strategies
Aug 12,2025 12:06
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
FGEN has released its 2025 Q3 earnings. EPS was reported at -3.25, versus the expected -4.01, beating expectations. The chart below visualizes how FGEN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FGEN has released its 2025 Q3 earnings report, with revenue of 1.08M, reflecting a YoY change of 774.80%, and net profit of 200.64M, showing a YoY change of 1274.41%. The Sankey diagram below clearly presents FGEN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
